ARTICLE | Clinical News

Activase tissue plasminogen activator data

November 15, 1993 8:00 AM UTC

Superior benefits from Activase versus the streptokinase-containing APSAC clot dissolver were reported. One-year follow up of the 382-patient TIMI-4 trial found that 6.8 percent of the t-PA group died, compared to 19 percent in the APSAC group (p < 0.02). A combination of APSAC and t-PA gave 13.3 percent mortality at one year. ...